Resistance to integrase inhibitors;Resistencia a los inhibidores de la integrasa

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 12, 2008, Pages 40-46

  Garrido, Carolina ^a   De Mendoza, Carmen ^a   Soriano, Vicente ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

HIV; Integrase; Raltegravir; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; QUINOLONE DERIVATIVE;

CROSS RESISTANCE; DRUG RESISTANCE; GENETIC RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL LITERATURE; MUTATION; NONHUMAN; REVIEW; SEQUENCE ANALYSIS; VIROLOGY; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECT; ENZYMOLOGY; GENETIC VARIABILITY; GENETICS; HUMAN; MISSENSE MUTATION; MULTIDRUG RESISTANCE; POINT MUTATION; PROTEIN CONFORMATION;

AMINO ACID SUBSTITUTION; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; HIV; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MODELS, MOLECULAR; MUTATION, MISSENSE; POINT MUTATION; PROTEIN CONFORMATION; PYRROLIDINONES; QUINOLONES;

EID: 68349159308     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76572-8     Document Type: Article

References (35)

1. V. DeGruttola, L. Dix, R. D'Aquila, D. Holder, A. Phillips, and M. Ait-Khaled The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standarized data analysis plan Antivir Ther 5 2000 41 48 (Pubitemid 30261205)
2. C. De Mendoza, C. Garrido, A. Corral, G. Ramírez-Olivencia, I. Jiménez-Nacher, and N. Zahonero Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients AIDS Res Hum Retroviruses 23 2007 879 885 (Pubitemid 47267494)
3. V. Miller, and B. Larder Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure Antivir Ther 6 2001 25 44 (Pubitemid 32938761)
4. C.F. Perno, G. Moyle, C. Tsoukas, W. Ratanasuwan, J. Gatell, and M. Schechter Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs J Med Virol 80 2008 565 576 (Pubitemid 351358551)
5. D. Hazuda, M. Miller, B. Nguyen, and J. Zhao Resistance to the HIV integrase inhibitor raltegravir: analysis of protocol 005, a phase 2 study in patients with triple-class resistant HIV-1 infection [Abstract 8] 16th International HIV Drug Resistance Workshop Barbados, 12-16 june 2007
6. M. Markowitz, B. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, and C. Kovacs Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study J Acquir Immune Defic Syndr 46 2007 125 133 (Pubitemid 47482607)
7. D. Cooper, J. Gatell, J. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, et al. for the BENCHMRK-1 Study Group 48-Week Results from BENCHMRK-1, a Phase III Study of Raltegravir in Patients Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1 [Abstract 788] 15th Conference on Retroviruses and Opportunistic Infections Boston 2008
8. R. Steigbigel, P. Kumar, J. Eron, M. Schechter, M. Markowitz, M. Loutfy, et al. for the BENCHMRK-2 Study Group 48-Week Results from BENCHMRK-2, a Phase III Study of Raltegravir in Patients Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1 [Abstract 789] 15th Conference on Retroviruses and Opportunistic Infections Boston 2008
9. I. Malet, O. Delelis, M. Valantin, B. Montes, C. Soulie, M. Wirden, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro Antimicrob Agents Chemother 52 2008 1351 1358
10. C. Charpentier, M. Karmochkine, D. Laureillard, P. Tisserand, L. Bélec, L. Weiss, et al. Drug resistance profiles of HIV integrase gene in patients failing Raltegravir-salvage therapy [Abstract 48] 6th European HIV Drug Resistance Workshop Budapest, 26-28 March 2008
11. C. Garrido, F. Blanco, K. Van Baelen, N. Zahonero, J. González-Lahoz, J. Villacian, et al. Raltegravir clinical response and resistance in heavily experienced patients [Abstract 52] 6th European HIV Drug Resistance Workshop Budapest, 26-28 March 2008
12. D. Mc Coll, S. Fransen, S. Gupta, N. Parkin, N. Margot, R. Ledford, et al. Resistance and cross-resistance to first generation integrase inhibitors: Insights form a Phase 2 study of Elvitegravir (GS-9137) [Abstract 9] 16th International HIV Drug Resistance Workshop Barbados, 12-16 June 2007
13. S. Deeks, S. Kar, S. Gubernick, and P. Kirkpatrick Raltegravir Nature Rev 7 2008 117 118 (Pubitemid 351194059)
14. E. Rondelez, K. Van Baelen, F. Ceccherini-Silverstein, V. Van Eygen, P. Van den Zegel, B. Winters, et al. Preliminary biological cut-offs for GS-9137 and MK-0518 integrase inhibitors derived from clonal phenotypic analysis [Abstract 73] 6th European HIV Drug Resistance Workshop Budapest, 26-28 March 2008
15. E. Poveda, V. Briz, D. Paraskevis, P. Barreiro, A. Hatzakis, and V. Soriano Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy AIDS Res Hum Retroviruses 23 2007 1078 1082 (Pubitemid 47571945)
16. G. Jones, R. Ledford, F. Yu, M. Miller, M. Tsiang, and D. McColl Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor GS- 9137 (JTK-303) [Abstract 627] 14th Conference on Retrovirus and Opportunistic Infections Los Angeles, 25-28 February 2007
17. D. Hazuda, P. Felock, M. Witmer, A. Wolfe, K. Stillmock, and J. Grobler Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells Science 287 2000 646 650 (Pubitemid 30070911)
18. E. DeJesus, C. Cohen, R. Elion, R. Ortiz, L. Haroldo, S. Franson, et al. First report of raltegravir (RAL, MK-0518) use alter virologic rebound on elvitegravir (EVT, GS-9137) [Abstract TUPEB032] 4th IAS Conference on HIV Sydney 2007 22-25 July
19. J. Wai, T. Fisher, M. Embrey, M. Egbertson, J. Vacca, D. Hazuda, et al. Next generation of inhibitors of HIV-1 integrase strand transfer inhibitor: Structural diversity and resistance profiles [Abstract 87] 14th Conference on Retrovirus and Opportunistic Infections Los Angeles, 25-28 February 2007
20. M. Lataillade, J. Chiarella, and M. Kozal Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance Antivir Ther 12 2007 563 570 (Pubitemid 47041156)
21. A. Low, H. Mohri, and M. Markowitz Frequency of naturally occurring polymorphisms associated with resistance to integrase inhibitors in a recently infected cohort [Abstract 625] 14th Conference on Retrovirus and Opportunistic Infections Los Angeles, 25-28 February 2007
22. R. Zioni, S. Rhee, T. Liu, and R. Shafer Natural variation of HIV-1 group M Integrase: Implications for integrase inhibitor therapy [Abstract 623] 14th Conference on Retrovirus and Opportunistic Infections Los Angeles, 25-28 February 2007
23. C. Garrido, A.M. Geretti, C. De Mendoza, C. Booth, A. Strang, and V. Soriano Polymorphisms at the integrase gene in distinct HIV populations may influence the susceptibility to integrase inhibitors [Abstract 12] 6th European HIV Drug Resistance Workshop Budapest, 26-28 March 2008
24. J. Hackett, B. Harris, V. Holzmayer, J. Yamaguchi, C. Luk K, C. Brennan, et al. Naturally occurring polymorphisms in HIV-1 group M, N, and O integrase: implications for integrase inhibitors [Abstract 872] 15th Conference on Retroviruses and Opportunistic Infections Boston 2008
25. N. Sichtig, M. Däumer, S. Esser, U. Dittmer, E. Schülter, M. Oette, et al. Analysis of integrase inhibitor (INI) resistance of HIV-1 group M in ARTnaïve and -experienced but INI-naïve patients in Germany [Abstract 67] 6th European HIV Drug Resistance Workshop Budapest, 26-28 March 2008
26. B. Roquebert, F. Damond, G. Collin, S. Matheron, A. Taieb, G. Peytavin, et al, The French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2) Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors: raltegravir and elvitegravir [Abstract 83] Antivir Ther 12 2007 S92
27. V. Briz, C. Garrido, J. Morello, C. De Mendoza, and V. Soriano Etravirine and Raltegravir are active against HIV-1 group O [Abstract 71] 6th European HIV Drug Resistance Workshop Budapest, 26-28 March 2008
28. Martínez-Picado J, Martínez MA. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. Virus Res. 2008 [en prensa].
29. M. Buzón, S. Marfil, M. Puertas, E. García, B. Clotet, J. Blanco, et al. Evolution of HIV-1 pol under HAART does not restrict fitness progression of HIV-1 integrase [Abstract 49] 6th European HIV Drug Resistance Workshop Budapest, 26-28 March 2008
30. B. Grinsztejn, B. Nguyen, C. Katlama, J.M. Gatell, A. Lazzarin, and D. Vittecoq Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial Lancet 369 2007 1261 1269 (Pubitemid 46553846)
31. S. Arponen, J. Benito, S. Lozano, F. Blanco, C. Garrido, C. De Mendoza, et al. More pronounced effect of integrase inhibitor raltegravir on proviral DNA reduction that other antiretroviral drugs in patients achieving undetectable viremia [Abstract 796] 15th Conference on Retroviruses and Opportunistic Infections Boston 2008
32. K. Shimura, E. Kodama, Y. Sakagami, Y. Matsuzaki, W. Watanabe, K. Yamataka, et al. Broad antiretroviral activity and resistance profile of the novel HIV integrase inhibitor elvitegravir (JTK-303/GS-9137) J Virol 82 2008 764 774
33. K. Van Laethem, Y. Schrooten, K. Covens, N. Dekeersmaeker, P. De Munter, E. Van Wijngaerden, et al. A genotypic assay for the amplification and sequencing of integrase from diverse HIV type 1 group M subtypes [Abstract 78] 6th European HIV Drug Resistance Workshop Budapest, 26-28 March 2008
34. P. Smith, V. Holzmayer, L. Fang, P. Swanson, J. Hackett, and N. Marlowe Performance of prototype integrase genotyping reagents for analysis of diverse HIV-1 strains [Abstract 881] 15th Conference on Retroviruses and Opportunistic Infections Boston 2008
35. Guía de Resistencias a los Antirretrovirales. Interpretació n de genotipos de resistencia de la Red de Investigación en SIDA (RIS). Barcelona: Permanyer; 2007.